Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (16.8), the stock would be worth HK$-12.43 (174% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -22.5 | HK$16.71 |
0%
|
| 3-Year Average | 16.8 | HK$-12.43 |
-174%
|
| 5-Year Average | 12.8 | HK$-9.49 |
-157%
|
| Industry Average | 30.7 | HK$-22.75 |
-236%
|
| Country Average | 28.8 | HK$-21.35 |
-228%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874
|
37.2B HKD | -22.5 | 12.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 153.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 35.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 24.5 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 12 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stands as a prominent player in China's healthcare industry, weaving a rich legacy that dates back to its formation in the 20th century. Rooted in the dynamic city of Guangzhou, Baiyunshan reflects a harmonious blend of traditional Chinese medicine (TCM) and modern pharmaceutical innovation. The company's name itself, Baiyunshan—meaning "White Cloud Mountain" in Chinese—symbolizes its foundational connection to the city's cultural heritage and its aspiration to elevate healthcare standards. Baiyunshan's operations are a testament to its multifaceted approach to pharmaceutical production. It delves into the research and development, manufacturing, and distribution of both TCM and Western medicine. This dual approach enables Baiyunshan to cater to a diverse demographic, forging a unique path by merging ancient medical wisdom with cutting-edge scientific advancements. The core of Baiyunshan's business strategy pivots around its expansive product portfolio, which is instrumental in its revenue generation. Pharmaceuticals are at its heart, encompassing a wide range of products from patent medicines to essential drugs that are household names in China. Additionally, the company has successfully branched into the production of over-the-counter (OTC) products, health supplements, and even skincare products, broadening its consumer reach. Meanwhile, Baiyunshan's distribution network—extensive and strategically aligned—stretches across domestic and international markets, ensuring its products are widely accessible. By leveraging strategic partnerships and ongoing innovation, the company continually fortifies its market presence, making Baiyunshan a notable financial performer and a beacon of trust in the healthcare industry.